Biomarkers of inflammatory bowel disease

Disease Markers

Volumn 2014, Issue , 2014, Pages

  Fengming, Yi ^a   Jianbing, Wu ^a  

^a NANCHANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ANGIOGENIN; BACTERIUM ANTIBODY; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM BINDING PROTEIN; CALGRANULIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CD14 ANTIGEN; CHITINASE; CHITINASE 3 LIKE 1; FECAL NEOPTERIN; INDOLEAMINE 2,3 DIOXYGENASE; INFLIXIMAB; INTERLEUKIN 23 RECEPTOR; LACTOFERRIN; LIPOPOLYSACCHARIDE BINDING PROTEIN; MICRORNA; MOPTERIN; NEOPTERIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; NITRIC OXIDE; S100A12 PROTEIN; SALICYLIC ACID; ST2 PROTEIN; SUBSTANCE P; THIOPURINE METHYLTRANSFERASE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TIOGUANINE; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; UNCLASSIFIED DRUG;

AUTOPHAGY; CELLULAR DISTRIBUTION; DISEASE ACTIVITY; DISEASE MARKER; DRUG METABOLISM; DRUG URINE LEVEL; ERYTHROCYTE; ERYTHROCYTE SEDIMENTATION RATE; GENETIC MARKER; GENETIC PREDISPOSITION; GLYCOSYLATION; HUMAN; IMMUNOCHEMISTRY; INFLAMMATORY BOWEL DISEASE; META ANALYSIS (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE COUNT; THROMBOCYTE VOLUME; FECES; GENETICS; IMMUNOLOGY; METABOLISM;

BIOLOGICAL MARKERS; FECES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84902161756     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2014/710915     Document Type: Review

References (136)

1. Vermeire S., van Assche G., Rutgeerts P., Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006 55 3 426 431 2-s2.0-33144460914 10.1136/gut.2005.069476
2. Khor B., Gardet A., Xavier R. J., Genetics and pathogenesis of inflammatory bowel disease. Nature 2011 474 7351 307 317 2-s2.0-79959216005 10.1038/nature10209
3. Carbonnel F., Macaigne G., Beaugerie L., Gendre J. P., Cosnes J., Crohn's disease severity in familial and sporadic cases. Gut 1999 44 1 91 95 2-s2.0-0033034042
4. Cho J. H., Brant S. R., Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011 140 6 1704 1712 2-s2.0-79955566359 10.1053/j.gastro.2011.02.046
5. Ogura Y., Bonen D. K., Inohara N., Nicolae D. L., Chen F. F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R. H., Achkar J.-P., Brant S. R., Bayless T. M., Kirschner B. S., Hanauer S. B., Nũez G., Cho J. H., A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001 411 6837 603 606 2-s2.0-0035978533 10.1038/35079114
6. Ng S. C., Tsoi K. K., Kamm M. A., Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis. Inflammatory Bowel Diseases 2012 18 6 1164 1176 10.1002/ibd.21845
7. Economou M., Trikalinos T. A., Loizou K. T., Tsianos E. V., Ioannidis J. P. A., Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. The American Journal of Gastroenterology 2004 99 12 2393 2404 2-s2.0-11144279151 10.1111/j.1572-0241. 2004.40304.x
8. Barrett J. C., Hansoul S., Nicolae D. L., Cho J. H., Duerr R. H., Rioux J. D., Brant S. R., Silverberg M. S., Taylor K. D., Barmada M. M., Bitton A., Dassopoulos T., Datta L. W., Green T., Griffiths A. M., Kistner E. O., Murtha M. T., Regueiro M. D., Rotter J. I., Schumm L. P., Steinhart A. H., Targan S. R., Xavier R. J., Libioulle C., Sandor C., Lathrop M., Belaiche J., Dewit O., Gut I., Heath S., Laukens D., Mni M., Rutgeerts P., van Gossum A., Zelenika D., Franchimont D., Hugot J.-P., de Vos M., Vermeire S., Louis E., Cardon L. R., Anderson C. A., Drummond H., Nimmo E., Ahmad T., Prescott N. J., Onnie C. M., Fisher S. A., Marchini J., Ghori J., Bumpstead S., Gwilliam R., Tremelling M., Deloukas P., Mansfield J., Jewell D., Satsangi J., Mathew C. G., Parkes M., Georges M., Daly M. J., Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nature Genetics 2008 40 8 955 962 2-s2.0-48349136889 10.1038/ng.175
9. Parkes M., Barrett J. C., Prescott N. J., Tremelling M., Anderson C. A., Fisher S. A., Roberts R. G., Nimmo E. R., Cummings F. R., Soars D., Drummond H., Lees C. W., Khawaja S. A., Bagnall R., Burke D. A., Todhunter C. E., Ahmad T., Onnie C. M., McArdle W., Strachan D., Bethel G., Bryan C., Lewis C. M., Deloukas P., Forbes A., Sanderson J., Jewell D. P., Satsangi J., Mansfield J. C., Cardon L., Mathew C. G., Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nature Genetics 2007 39 7 830 832 2-s2.0-34347338690 10.1038/ng2061
10. Cheon J. H., Genetics of inflammatory bowel diseases: a comparison between Western and Eastern perspectives. Journal of Gastroenterology and Hepatology 2013 28 2 220 226 10.1111/jgh.12053
11. Prescott N. J., Dominy K. M., Kubo M., Lewis C. M., Fisher S. A., Redon R., Huang N., Stranger B. E., Blaszczyk K., Hudspith B., Parkes G., Hosono N., Yamazaki K., Onnie C. M., Forbes A., Dermitzakis E. T., Nakamura Y., Mansfield J. C., Sanderson J., Hurles M. E., Roberts R. G., Mathew C. G., Independent and population-specific association of risk variants at the IRGM locus with Crohn's disease. Human Molecular Genetics 2010 19 9 1828 1839 2-s2.0-77952515610 10.1093/hmg/ddq041 ddq041
12. Moon C. M., Shin D. J., Kim S. W., Associations between genetic variants in the IRGM gene and inflammatory bowel diseases in the Korean population. Inflammatory Bowel Diseases 2013 19 1 106 114 10.1002/ibd.22972
13. Yamazaki K., Onouchi Y., Takazoe M., Kubo M., Nakamura Y., Hata A., Association analysis of genetic variants in IL23R, ATG16L1 and 5p13.1 loci with Crohn's disease in Japanese patients. Journal of Human Genetics 2007 52 7 575 583 2-s2.0-34347357508 10.1007/s10038-007-0156-z
14. Yang S.-K., Park M., Lim J., Park S. H., Ye B. D., Lee I., Song K., Contribution of IL23R but not ATG16L1 to Crohn's disease susceptibility in Koreans. Inflammatory Bowel Diseases 2009 15 9 1385 1390 2-s2.0-70449719062 10.1002/ibd.20921
15. Bin C., Zhirong Z., Xiaoqin W., Minhu C., Mei L., Xiang G., Baili C., Pinjin H., Contribution of rs11465788 in IL23R gene to Crohn's disease susceptibility and phenotype in Chinese population. Journal of Genetics 2009 88 2 191 196 2-s2.0-70350754566 10.1007/s12041-009-0027-9
16. Jürgens M., Laubender R. P., Hartl F., Weidinger M., Seiderer J., Wagner J., Wetzke M., Beigel F., Pfennig S., Stallhofer J., Schnitzler F., Tillack C., Lohse P., Göke B., Glas J., Ochsenkühn T., Brand S., Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. The American Journal of Gastroenterology 2010 105 8 1811 1819 2-s2.0-77955426386 10.1038/ajg.2010.95
17. Rump J. A., Scholmerich J., Gross V., Roth M., Helfesrieder R., Rautmann A., Ludemann J., Gross W. L., Peter H. H., A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology 1990 181 4-5 406 413 2-s2.0-0025615162
18. Vidrich A., Lee J., James E., Cobb L., Targan S., Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. Journal of Clinical Immunology 1995 15 6 293 299 2-s2.0-0028784646 10.1007/BF01541319
19. Prideaux L., de Cruz P., Ng S. C., Kamm M. A., Serological antibodies in inflammatory bowel disease: a systematic review. Inflammatory Bowel Diseases 2012 18 7 1340 1355 10.1002/ibd.21903
20. Joossens S., Reinisch W., Vermeire S., Sendid B., Poulain D., Peeters M., Geboes K., Bossuyt X., Vandewalle P., Oberhuber G., Vogelsang H., Rutgeerts P., Colombel J., The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002 122 5 1242 1247 2-s2.0-0036242774
21. Bernstein C. N., El-Gabalawy H., Sargent M., Landers C. J., Rawsthorne P., Elias B., Targan S. R., Assessing inflammatory bowel disease-associated antibodies in Caucasian and First Nations cohorts. Canadian Journal of Gastroenterology 2011 25 5 269 273 2-s2.0-79959811829
22. Zhou F., Xia B., Wang F., Shrestha U. K., Chen M., Wang H., Shi X., Chen Z., Li J., The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China. Clinica Chimica Acta 2010 411 19-20 1461 1465 2-s2.0-77955055367 10.1016/j.cca.2010.05.041
23. Sendid B., Colombel J. F., Jacquinot P. M., Faille C., Fruit J., Cortot A., Lucidarme D., Camus D., Poulain D., Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clinical and Diagnostic Laboratory Immunology 1996 3 219 226
24. Mallant-Hent R. C., Mooij M., von Blomberg B. M. E., Linskens R. K., van Bodegraven A. A., Savelkoul P. H. M., Correlation between Saccharomyces cerevisiae DNA in intestinal mucosal samples and anti-Saccharomyces cerevisiae antibodies in serum of patients with IBD. World Journal of Gastroenterology 2006 12 2 292 297 2-s2.0-33644750713
25. Abbasian J., Martin T. M., Patel S., Tessler H. H., Goldstein D. A., Immunologic and genetic markers in patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease. American Journal of Ophthalmology 2012 154 1 72 77 10.1016/j.ajo.2012.01.016
26. Lakatos P. L., Papp M., Rieder F., Serologic antiglycan antibodies in inflammatory bowel disease. The American Journal of Gastroenterology 2011 106 3 406 412 2-s2.0-79952361823 10.1038/ajg.2010.505
27. Bogdanos D. P., Rigopoulou E. I., Smyk D. S., Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies. Autoimmunity Reviews 2011 11 2 143 148 10.1016/j.autrev.2011.09.004
28. Zholudev A., Zurakowski D., Young W., Leichtner A., Bousvaros A., Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. American Journal of Gastroenterology 2004 99 11 2235 2241 2-s2.0-8744262944 10.1111/j.1572-0241.2004.40369.x
29. Tillett W. S., Francis T., Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. The Journal of Experimental Medicine 1930 52 4 561 571 10.1084/jem.52.4.561
30. Rudolph W. G., Uthoff S. M., McAuliffe T. L., Goode E. T., Petras R. E., Galandiuk S., Indeterminate colitis: the real story. Diseases of the Colon and Rectum 2002 45 11 1528 1534 2-s2.0-0036847807 10.1007/s10350-004-6461-0
31. Abdelrazeq A. S., Wilson T. R., Leitch D. L., Lund J. N., Leveson S. H., Ileitis in ulcerative colitis: is it a backwash? Diseases of the Colon and Rectum 2005 48 11 2038 2046 2-s2.0-29844456688 10.1007/s10350-005-0160-3
32. Yamamoto-Furusho J. K., Camacho-Escobedo J., Téllez-Ávila F., Barreto R., β 2 microglobulin levels and high sensitive C-reactive protein as markers of histological activity in patients with chronic idiopathic ulcerative colitis. Gaceta Medica de Mexico 2010 146 1 31 35 2-s2.0-77954273759
33. Sidoroff M., Karikoski R., Raivio T., Savilahti E., Kolho K.-L., High-sensitivity C-reactive protein in paediatric inflammatory bowel disease. World Journal of Gastroenterology 2010 16 23 2901 2906 2-s2.0-77954268512 10.3748/wjg.v16.i23.2901
34. Thomas R. D., Westengard J. C., Hay K. L., Bull B. S., Calibration and validation for erythrocyte sedimentation tests: role of the International Committee on Standardization in Hematology reference procedure. Archives of Pathology and Laboratory Medicine 1993 117 7 719 723 2-s2.0-0027254459
35. Danese S., de la Motte C., Fiocchi C., Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. The American Journal of Gastroenterology 2004 99 5 938 945 2-s2.0-2942666368 10.1111/j.1572-0241.2004.04129.x
36. Collins C. E., Rampton D. S., Platelet dysfunction: a new dimension in inflammatory bowel disease. Gut 1995 36 1 5 8 2-s2.0-0028832942
37. Dong W.-G., Liu S.-P., Zhu H.-H., Luo H.-S., Yu J.-P., Abnormal function of platelets and role of angelica sinensis in patients with ulcerative colitis. World Journal of Gastroenterology 2004 10 4 606 609 2-s2.0-1542314887
38. Kayahan H., Akarsu M., Ozcan M. A., Demir S., Ates H., Unsal B., Akpinar H., Reticulated platelet levels in patients with ulcerative colitis. International Journal of Colorectal Disease 2007 22 12 1429 1435 2-s2.0-35148849670 10.1007/s00384-007-0330-y
39. Kapsoritakis A. N., Koukourakis M. I., Sfiridaki A., Potamianos S. P., Kosmadaki M. G., Koutroubakis I. E., Kouroumalis E. A., Mean platelet volume: a useful marker of inflammatory bowel disease activity. The American Journal of Gastroenterology 2001 96 3 776 781 2-s2.0-0035068299 10.1016/S0002-9270(00) 02414-X
40. Zubcevic N., Mesihovic R., Zubcevic S., Usefulness of laboratory data in estimation of Crohn's disease activity. Medicinski Arhiv 2010 64 1 33 36 2-s2.0-77952317863
41. Karnad A., Poskitt T. R., The automated complete blood cell count. Use of the red blood cell volume distribution width and mean platelet volume in evaluating anemia and thrombocytopenia. Archives of Internal Medicine 1985 145 7 1270 1272 2-s2.0-0021966793 10.1001/archinte.145.7.1270
42. Song C. S., Park D. I., Yoon M. Y., Association between red cell distribution width and disease activity in patients with inflammatory bowel disease. Digestive Diseases and Sciences 2012 57 4 1033 1038 10.1007/s10620-011-1978-2
43. Oustamanolakis P., Koutroubakis I. E., Messaritakis I., Kefalogiannis G., Niniraki M., Kouroumalis E. A., Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease. Journal of Crohn's and Colitis 2011 5 4 295 300 2-s2.0-79958800735 10.1016/j.crohns.2011. 02.002
44. Fagerhol M. K., Dale I., Andersson T., A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bulletin Europeen de Physiopathologie Respiratoire 1980 16 supplement 273 282 2-s2.0-0019268759
45. Roseth A. G., Fagerhol M. K., Aadland E., Schjonsby H., Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scandinavian Journal of Gastroenterology 1992 27 9 793 798 2-s2.0-0026744132
46. Smith L. A., Gaya D. R., Utility of faecal calprotectin analysis in adult inflammatory bowel disease. World Journal of Gastroenterology 2012 18 46 6782 6789 10.3748/wjg.v18.i46.6782
47. Tibble J., Teahon K., Thjodleifsson B., Roseth A., Sigthorsson G., Bridger S., Foster R., Sherwood R., Fagerhol M., Bjarnason I., A simple method for assessing intestinal inflammation in Crohn's disease. Gut 2000 47 4 506 513 2-s2.0-0033795259 10.1136/gut.47.4.506
48. Schoepfer A. M., Trummler M., Seeholzer P., Seibold-Schmid B., Seibold F., Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflammatory Bowel Diseases 2008 14 1 32 39 2-s2.0-38849194737 10.1002/ibd.20275
49. von Roon A. C., Karamountzos L., Purkayastha S., Reese G. E., Darzi A. W., Teare J. P., Paraskeva P., Tekkis P. P., Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. The American Journal of Gastroenterology 2007 102 4 803 813 2-s2.0-33947683926 10.1111/j.1572-0241.2007.01126.x
50. van Rheenen P. F., Van de Vijver E., Fidler V., Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. British Medical Journal 2010 341 c3369 2-s2.0-77954964440 10.1136/bmj.c3369
51. Sipponen T., Savilahti E., Kolho K.-L., Nuutinen H., Turunen U., Färkkilä M., Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflammatory Bowel Diseases 2008 14 1 40 46 2-s2.0-38849204268 10.1002/ibd.20312
52. Ricanek P., Brackmann S., Perminow G., Lyckander L. G., Sponheim J., Holme Ø., Høie O., Rydning A., Vatn M. H., Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers. Scandinavian Journal of Gastroenterology 2011 46 9 1081 1091 2-s2.0-80051778056 10.3109/00365521.2011.584897
53. Sipponen T., Bjrkesten C.-G. A., Färkkilä M., Nuutinen H., Savilahti E., Kolho K.-L., Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scandinavian Journal of Gastroenterology 2010 45 3 325 331 2-s2.0-77149154328 10.3109/00365520903483650
54. Sipponen T., Savilahti E., Kärkkäinen P., Kolho K.-L., Nuutinen H., Turunen U., Färkkilä M., Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflammatory Bowel Diseases 2008 14 10 1392 1398 2-s2.0-54049150524 10.1002/ibd.20490
55. Røseth A. G., Aadland E., Grzyb K., Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2004 39 10 1017 1020 2-s2.0-6344246551 10.1080/00365520410007971
56. Mao R., Xiao Y. L., Gao X., Chen B. L., He Y., Yang L., Hu P. J., Chen M. H., Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflammatory Bowel Diseases 2012 18 10 1894 1899 10.1002/ibd.22861
57. Shaoul R., Sladek M., Turner D., Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn's disease. Inflammatory Bowel Diseases 2012 18 8 1493 11497 10.1002/ibd.21875
58. Hämäläinen A., Sipponen T., Kolho K.-L., Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World Journal of Gastroenterology 2011 17 47 5166 5171 2-s2.0-83755194964 10.3748/wjg.v17.i47.5166
59. Koulaouzidis A., Douglas S., Rogers M. A., Arnott I. D., Plevris J. N., Fecal calprotectin: a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy. Scandinavian Journal of Gastroenterology 2011 46 5 561 566 2-s2.0-79954476797 10.3109/00365521.2011. 551835
60. Burri E., Manz M., Schroeder P., Froehlich F., Rossi L., Beglinger C., Lehmann F. S., Diagnostic yield of endoscopy in patients with abdominal complaints: incremental value of faecal calprotectin on guidelines of appropriateness. BMC Gastroenterology 2014 14 article 57
61. Waugh N., Cummins E., Royle P., Kandala N. B., Shyangdan D., Arasaradnam R., Clar C., Johnston R., Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technology Assessment 2013 17 55 1 211
62. NICE, Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. NICE Diagnostics Guidance 11 2013 1 58
63. Baveye S., Elass E., Mazurier J., Spik G., Legrand D., Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clinical Chemistry and Laboratory Medicine 1999 37 3 281 286 2-s2.0-0032893748 10.1515/CCLM.1999.049
64. Baynes R. D., Bezwoda W. R., Lactoferrin and the inflammatory response. Advances in Experimental Medicine and Biology 1994 357 133 141 2-s2.0-0028618679
65. Kane S. V., Sandborn W. J., Rufo P. A., Zholudev A., Boone J., Lyerly D., Camilleri M., Hanauer S. B., Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. The American Journal of Gastroenterology 2003 98 6 1309 1314 2-s2.0-0037635274 10.1111/j.1572-0241.2003. 07458.x
66. Desai D., Faubion W. A., Sandborn W. J., Review article: biological activity markers in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2007 25 3 247 255 2-s2.0-33846312085 10.1111/j.1365-2036.2006. 03184.x
67. Joishy M., Davies I., Ahmed M., Wassel J., Davies K., Sayers A., Jenkins H., Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition 2009 48 1 48 54 2-s2.0-63649103959 10.1097/MPG.0b013e31816533d3
68. Sugi K., Saitoh O., Hirata I., Katsu K., Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. The American Journal of Gastroenterology 1996 91 927 934
69. Langhorst J., Elsenbruch S., Koelzer J., Rueffer A., Michalsen A., Dobos G. J., Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. The American Journal of Gastroenterology 2008 103 1 162 169 2-s2.0-37849053698 10.1111/j.1572-0241.2007. 01556.x
70. Dai J., Liu W.-Z., Zhao Y.-P., Hu Y.-B., Ge Z.-Z., Relationship between fecal lactoferrin and inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2007 42 12 1440 1444 2-s2.0-36249011408 10.1080/ 00365520701427094
71. Nancey S., Boschetti G., Moussata D., Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflammatory Bowel Diseases 2013 19 5 1043 1052
72. Husain N., Tokoro K., Popov J. M., Naides S. J., Kwasny M. J., Buchman A. L., Neopterin concentration as an index of disease activity in Crohn's disease and ulcerative colitis. Journal of Clinical Gastroenterology 2013 47 3 246 251 10.1097/MCG.0b013e3182582cdb
73. van de Logt F., Day A. S., S100A12: a noninvasive marker of inflammation in inflammatory bowel disease. Journal of Digestive Diseases 2013 14 2 62 67
74. Donato R., Intracellular and extracellular roles of S100 proteins. Microscopy Research and Technique 2003 60 6 540 551 2-s2.0-0142229704
75. Hofmann M. A., Drury S., Fu C., Qu W., Taguchi A., Lu Y., Avila C., Kambham N., Bierhaus A., Nawroth P., Neurath M. F., Slattery T., Beach D., McClary J., Nagashima M., Morser J., Stern D., Schmidt A. M., RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999 97 7 889 901 2-s2.0-0033603241 10.1016/S0092-8674(00) 80801-6
76. Perera C., McNeil H. P., Geczy C. L., S100 Calgranulins in inflammatory arthritis. Immunology and Cell Biology 2010 88 1 41 49 2-s2.0-74249122809 10.1038/icb.2009.88
77. Ye F., Foell D., Hirono K.-I., Vogl T., Rui C., Yu X., Watanabe S., Watanabe K., Uese K.-I., Hashimoto I., Roth J., Ichida F., Miyawaki T., Neutrophil-derived S100A12 is profoundly upregulated in the early stage of acute Kawasaki disease. The American Journal of Cardiology 2004 94 6 840 844 2-s2.0-4544333406 10.1016/j.amjcard.2004.05.076
78. Loughran-Fowlds A., Leach S., Lin J., Oei J., Henry R., Day A. S., Lui K., Respiratory disease and early serum S100A12 changes in very premature infants. Acta Paediatrica 2011 100 12 1538 1543 2-s2.0-80855131452 10.1111/j.1651-2227.2011.02384.x
79. Stephens M., Batres A. L., Ng D., Baldassano R., Growth failure in the child with inflammatory bowel disease. Seminars in Gastrointestinal Disease 2001 12 4 253 262 2-s2.0-0034750293
80. de Jong N. S. H., Leach S. T., Day A. S., Fecal S100A12: a novel noninvasive marker in children with Crohn's disease. Inflammatory Bowel Diseases 2006 12 7 566 572 2-s2.0-33745524590 10.1097/01.ibd.0000227626.72271.91
81. Turner D., Leach S. T., Mack D., Uusoue K., McLernon R., Hyams J., Leleiko N., Walters T. D., Crandall W., Markowitz J., Otley A. R., Griffiths A. M., Day A. S., Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut 2010 59 9 1207 1212 2-s2.0-77956129180 10.1136/gut.2010.211755
82. Kaiser T., Langhorst J., Wittkowski H., Becker K., Friedrich A. W., Rueffer A., Dobos G. J., Roth J., Foell D., Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007 56 12 1706 1713 2-s2.0-36749098918 10.1136/gut.2006.113431
83. Foell D., Kucharzik T., Kraft M., Vogl T., Sorg C., Domschke W., Roth J., Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003 52 6 847 853 2-s2.0-0038576426 10.1136/gut.52.6.847
84. Sipponen T., Haapamaki J., Savilahti E., Alfthan H., Hämä läinen E., Rautiainen H., Koskenpato J., Nuutinen H., Färkkilä M., Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Scandinavian Journal of Gastroenterology 2012 47 7 778 784 10.3109/00365521.2012.677953
85. Manolakis A. C., Kapsoritakis A. N., Tiaka E. K., Potamianos S. P., Calprotectin, calgranulin C, and other members of the s100 protein family in inflammatory bowel disease. Digestive Diseases and Sciences 2011 56 6 1601 1611 2-s2.0-79959736367 10.1007/s10620-010-1494-9
86. Tomankova T., Petrek M., Gallo J., Kriegova E., MicroRNAs: emerging regulators of immune-mediated diseases. Scandinavian Journal of Immunology 2012 75 2 129 141 2-s2.0-84855718076 10.1111/j.1365-3083.2011.02650.x
87. Dalal S. R., Kwon J. H., The role of microRNA in inflammatory bowel disease. Gastroenterology and Hepatology 2010 6 11 714 722 2-s2.0-78650484049
88. Wu F., Guo N. J., Tian H., Marohn M., Gearhart S., Bayless T. M., Brant S. R., Kwon J. H., Peripheral blood MicroRNAs distinguish active ulcerative colitis and Crohn's disease. Inflammatory Bowel Diseases 2011 17 1 241 250 2-s2.0-78650119948 10.1002/ibd.21450
89. Maor I., Rainis T., Lanir A., Lavy A., Adenosine deaminase activity in patients with Crohn's disease: distinction between active and nonactive disease. European Journal of Gastroenterology and Hepatology 2011 23 7 598 602 2-s2.0-79960101569 10.1097/MEG.0b013e328346e205
90. Lakatos P. L., Kiss L. S., Palatka K., Altorjay I., Antal-Szalmas P., Palyu E., Udvardy M., Molnar T., Farkas K., Veres G., Harsfalvi J., Papp J., Papp M., Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease. Inflammatory Bowel Diseases 2011 17 3 767 777 2-s2.0-79951603051 10.1002/ibd.21402
91. Shinzaki S., Kuroki E., Iijima H., Lectin-based immunoassay for aberrant IgG glycosylation as the biomarker for Crohn's disease. Inflammatory Bowel Diseases 2013 19 2 321 331 10.1097/MIB.0b013e318280eade
92. Judmaier G., Meyersbach P., Weiss G., Wachter H., Reibnegger G., The role of neopterin in assessing disease activity in Crohn's disease: classification and regression trees. The American Journal of Gastroenterology 1993 88 5 706 711 2-s2.0-0027233721
93. Huber C., Batchelor J. R., Fuchs D., Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. The Journal of Experimental Medicine 1984 160 1 310 316 2-s2.0-0021264311
94. Prior Ch. P. C., Bollbach R., Fuchs D., Urinary neopterin, a marker of clinical activity in patients with Crohn's disease. Clinica Chimica Acta 1986 155 1 11 21 2-s2.0-0022477393
95. Konecny M., Ehrmann J., Bartek J., Hermanova Z., Krc I., The level of neopterin in blood serum as one of the possible prognostic markers of Crohn's disease activity. Acta Universitatis Palackianae Olomucensis Facultatis Medicae 1996 140 47 48
96. Nancey S., Perret-Liaudet A., Moussata D., Graber I., Boschetti G., Renaud B., Kaiserlian D., Reimund J. M., Flourié B., Urinary neopterin is a valuable tool in monitoring Crohn's disease activity. Inflammatory Bowel Diseases 2008 14 11 1548 1554 2-s2.0-59249085708 10.1002/ibd.20510
97. Niederwieser D., Fuchs D., Hausen A., Neopterin as a new biochemical marker in the clinical assessment of ulcerative colitis. Immunobiology 1985 170 4 320 326 2-s2.0-0022360040
98. Reimund J.-M., Arondel Y., Escalin G., Finck G., Baumann R., Duclos B., Immune activation and nutritional status in adult Crohn's disease patients. Digestive and Liver Disease 2005 37 6 424 431 2-s2.0-26944485212 10.1016/j.dld.2005.01.010
99. Li H., Tago K., Io K., Kuroiwa K., Arai T., Iwahana H., Tominaga S.-I., Yanagisawa K., The cloning and nucleotide sequence of human ST2L cDNA. Genomics 2000 67 3 284 290 2-s2.0-0034253797 10.1006/geno.2000.6269
100. Diaz-Jimenez D., Nunez L. E., Beltran C. J., Candia E., Suazo C., Alvarez-Lobos M., González M. J., Hermoso M. A., Quera R., Soluble ST2: a new and promising activity marker in ulcerative colitis. World Journal of Gastroenterology 2011 17 17 2181 2190 10.3748/wjg.v17.i17.2181
101. Avdagic N., Zaciragic A., Babic N., Hukic M., Seremet M., Lepara O., Nakaš-Ićindić E., Nitric oxide as a potential biomarker in inflammatory bowel disease. Bosnian Journal of Basic Medical Sciences 2013 13 1 5 9
102. Malerba M., Ragnoli B., Buffoli L., Radaeli A., Ricci C., Lanzarotto F., Lanzini A., Exhaled nitric oxide as a marker of lung involvement in Crohn's disease. International Journal of Immunopathology and Pharmacology 2011 24 4 1119 1124 2-s2.0-84856586418
103. Jung Y. S., Park J. J., Kim S. W., Hong S. P., Kim T. I., Kim W. H., Cheon J. H., Correlation between soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel diseases. Digestive and Liver Disease 2012 44 11 897 903 10.1016/j.dld.2012.05.011
104. Tavano F., di Mola F. F., Latiano A., Neuroimmune interactions in patients with inflammatory bowel diseases: disease activity and clinical behavior based on Substance P serum levels. Journal of Crohn's and Colitis 2012 6 5 563 570 10.1016/j.crohns.2011.11.004
105. Owczarek D., Undas A., Foley J. H., Nesheim M. E., Jabłonski K., Mach T., Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD. Journal of Crohn's and Colitis 2012 6 1 13 20 2-s2.0-84855948565 10.1016/j.crohns.2011.06.005
106. Nakarai A., Kato J., Hiraoka S., Kuriyama M., Akita M., Hirakawa T., Okada H., Yamamoto K., Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test. The American Journal of Gastroenterology 2013 108 83 89 10.1038/ajg.2012.315
107. Aomatsu T., Imaeda H., Matsumoto K., Kimura E., Yoden A., Tamai H., Fujiyama Y., Mizoguchi E., Andoh A., Faecal chitinase 3-like-1: a novel biomarker of disease activity in paediatric inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 2011 34 8 941 948 2-s2.0-80053188757 10.1111/j.1365-2036.2011.04805.x
108. Oikonomou K. A., Kapsoritakis A. N., Kapsoritaki A. I., Manolakis A. C., Tiaka E. K., Tsiopoulos F. D., Tsiompanidis I. A., Potamianos S. P., Angiogenin, angiopoietin-1, angiopoietin-2, and endostatin serum levels in inflammatory bowel disease. Inflammatory Bowel Diseases 2011 17 4 963 970 2-s2.0-79952481259 10.1002/ibd.21410
109. Ciorba M. A., Indoleamine 2,3 dioxygenase in intestinal disease. Current Opinion in Gastroenterology 2013 29 2 146 152 10.1097/MOG.0b013e32835c9cb3
110. Rismo R., Olsen T., Cui G., Christiansen I., Florholmen J., Goll R., Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Scandinavian Journal of Gastroenterology 2012 47 5 538 547 2-s2.0-84859606047 10.3109/00365521.2012.667146
111. + cells are significantly decreased in the duodenum, ileum and colon of dogs with inflammatory bowel disease. Journal of Comparative Pathology 2011 145 4 359 366 2-s2.0-80055008991 10.1016/j.jcpa.2011.03.010
112. Scaldaferri F., Correale C., Gasbarrini A., Danese S., Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors? World Journal of Gastroenterology 2010 16 21 2616 2625 2-s2.0-77953505281 10.3748/wjg.v16.i21.2616
113. Song W.-B., Lv Y.-H., Zhang Z.-S., Li Y.-N., Xiao L.-P., Yu X.-P., Wang Y.-Y., Ji H.-L., Ma L., Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease. World Journal of Gastroenterology 2009 15 31 3916 3919 2-s2.0-70350515024 10.3748/wjg.15.3916
114. Landers C. J., Cohavy O., Misra R., Yang H., Lin Y., Braun J., Targan S. R., Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002 123 3 689 699 2-s2.0-0036726184 10.1053/gast.2002.35379
115. Targan S. R., Landers C. J., Yang H., Lodes M. J., Cong Y., Papadakis K. A., Vasiliauskas E., Elson C. O., Hershberg R. M., Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005 128 7 2020 2028 2-s2.0-20444441016 10.1053/j.gastro.2005.03.046
116. Moran G. W., O'Neill C., Padfield P., McLaughlin J. T., Dipeptidyl peptidase-4 expression is reduced in Crohn's disease. Regulatory Peptides 2012 177 1-3 40 45 10.1016/j.regpep.2012.04.006
117. Nanda K. S., Cheifetz A. S., Moss A. C., Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. The American Journal of Gastroenterology 2013 108 quiz 48 40 47 10.1038/ajg.2012.363
118. Burri E., Beglinger C., Lehmann F. S., Monitoring of therapy for inflammatory bowel disease. Digestion 2012 86 supplement 1 1 5
119. Ben-Horin S., Yavzori M., Katz L., Kopylov U., Picard O., Fudim E., Coscas D., Bar-Meir S., Goldstein I., Chowers Y., The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011 60 1 41 48 2-s2.0-78651237721 10.1136/gut.2009.201533
120. González-Lama Y., Bermejo F., Lõpez-Sanromán A., García-Sánchez V., Esteve M., Cabriada J. L., McNicholl A. G., Pajares R., Casellas F., Merino O., Carpio D., Vera M. I., Muñoz C., Calvo M., Benito L. M., Bujanda L., García-Fernández F. J., Ricart E.,
121. Gifford A. E., Berg A. H., Lahiff C., Cheifetz A. S., Horowitz G., Moss A. C., A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study. The American Journal of Gastroenterology 2013 108 249 255 10.1038/ajg.2012.419
122. Potočnik U., Ferkolj I., Glavač D., Dean M., Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes and Immunity 2004 5 7 530 539 2-s2.0-8844229534 10.1038/sj.gene.6364123
123. Daniel F., Loriot M.-A., Seksik P., Cosnes J., Gornet J.-M., Lémann M., Fein F., Vernier-Massouille G., de Vos M., Boureille A., Treton X., Flourié B., Roblin X., Louis E., Zerbib F., Beaune P., Marteau P., Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflammatory Bowel Diseases 2007 13 1 19 23 2-s2.0-33846157742 10.1002/ibd.20046
124. Hlavaty T., Pierik M., Henckaerts L., Ferrante M., Joossens S., Van Schuerbeek N., Noman M., Rutgeerts P., Vermeire S., Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Alimentary Pharmacology and Therapeutics 2005 22 7 613 626 2-s2.0-26244456815 10.1111/j.1365-2036.2005.02635.x
125. Czub E., Herzig K.-H., Szaflarska-Popławska A., Kiehne K., Socha P., Woś H., Kamińska B., Błaszczyński M., Cichy W., Bała G., Brodzicki J., Grzybowska-Chlebowczyk U., Walkowiak J., Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 2007 42 10 1147 1150 2-s2.0-35148855386 10.1080/00365520701320513
126. Walkowiak J., Banasiewicz T., Krokowicz P., Hansdorfer-Korzon R., Drews M., Herzig K.-H., Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis. Scandinavian Journal of Gastroenterology 2005 40 12 1493 1494 2-s2.0-29744464361 10.1080/00365520500319112
127. McDowell G., Gupta S., Dellerba M., Coppinger T., Levy R. D., Keevil B. G., Plasma concentrations of tumour dimeric pyruvate kinase are increased in patients with chronic failure. Annals of Clinical Biochemistry 2004 41 6 491 493 2-s2.0-9644259065 10.1258/0004563042466712
128. Oehler R., Weingartmann G., Manhart N., Salzer U., Meissner M., Schlegel W., Spittler A., Bergmann M., Kandioler D., Oismüller C., Struse H. M., Roth E., Polytrauma induces increased expression of pyruvate kinase in neutrophils. Blood 2000 95 3 1086 1092 2-s2.0-12944257426
129. Hardt P. D., Mazurek S., Toepler M., Schlierbach P., Bretzel R. G., Eigenbrodt E., Kloer H. U., Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. British Journal of Cancer 2004 91 5 980 984 2-s2.0-4644265292 10.1038/sj.bjc.6602033
130. Chung-Faye G., Hayee B., Maestranzi S., Donaldson N., Forgacs I., Sherwood R., Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation. Inflammatory Bowel Diseases 2007 13 11 1374 1378 2-s2.0-36749059545 10.1002/ibd.20214
131. Taganov K. D., Boldin M. P., Chang K.-J., Baltimore D., NF- B-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proceedings of the National Academy of Sciences of the United States of America 2006 103 33 12481 12486 2-s2.0-33747608638 10.1073/pnas.0605298103
132. Fasseu M., Tréton X., Guichard C., Pedruzzi E., Cazals-Hatem D., Richard C., Aparicio T., Daniel F., Soulé J.-C., Moreau R., Bouhnik Y., Laburthe M., Groyer A., Ogier-Denis E., Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS ONE 2010 5 10 2-s2.0-78049340862 10.1371/journal.pone.0013160 e13160
133. Ludwig K., Fassan M., Mescoli C., PDCD4/miR-21 dysregulation in inflammatory bowel disease-associated carcinogenesis. Virchows Archiv 2013 462 1 57 63 10.1007/s00428-012-1345-5
134. Olaru A. V., Selaru F. M., Mori Y., Vazquez C., David S., Paun B., Cheng Y., Jin Z., Yang J., Agarwal R., Abraham J. M., Dassopoulos T., Harris M., Bayless T. M., Kwon J., Harpaz N., Livak F., Meltzer S. J., Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation. Inflammatory Bowel Diseases 2011 17 1 221 231 2-s2.0-78650108135 10.1002/ibd.21359
135. Wu C. W., Ng S. S. M., Dong Y. J., Ng S. C., Leung W. W., Lee C. W., Wong Y. N., Chan F. K. L., Yu J., Sung J. J. Y., Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 2012 61 5 739 745 2-s2.0-84859603174 10.1136/gut.2011.239236
136. Chen C.-C., Pekow J., Llado V., Kanneganti M., Lau C. W., Mizoguchi A., Mino-Kenudson M., Bissonnette M., Mizoguchi E., Chitinase 3-like-1 expression in colonic epithelial cells as a potentially novel marker for colitis-associated neoplasia. The American Journal of Pathology 2011 179 3 1494 1503 2-s2.0-80052855384 10.1016/j.ajpath.2011.05.038